Alcobra $ADHD reported that it has received the written full clinical hold notice from the FDA in relation to its Metadoxine Extended Release (MDX) in adult patients with attention deficit/hyperactivity disorder [ADHD]. Shares had plunged about 60% on September 29, when the company first verbally announced the FDA�s decision.